BioTuesdays

Category - Markets

Syros-Logo

HCW ups Syros to buy; PT to $15 from $11

H.C. Wainwright upgraded Syros Pharmaceuticals (NASDAQ:SYRS) to “buy” from “neutral” and upped its price target to $15 from $11, saying the company “has turned a corner, in our opinion.” The stock closed at $6.67 on Nov...

Heska-Corporation-Logo

AGP ups price target for Heska to $163.50 from $116.50

Alliance Global Partners raised its price target for Heska (NASDAQ:HSKA) to $163.50 from $116.50 after hosting an investor webcast with the company’s CEO. The stock closed at $116.41 on Nov. 3. Analyst Ben Haynor writes...

Spruce-Biosciences-Logo

SVB Leerink starts Spruce Biosciences at OP; PT $35

SVB Leerink launched coverage of Spruce Biosciences (NASDAQ:SPRB) with an “outperform” rating and $35 price target. The stock closed at $20.30 on Nov. 2 Spruce is a late-stage biotech company developing therapies for...

STRATA Skin Sciences

HCW ups STRATA Skin Sciences to buy; PT $3

H.C. Wainwright upgraded STRATA Skin Sciences (NASDAQ:SSKN) to “buy” from “neutral” with a price target of $3. The stock closed at $1.24 on Nov. 2. STRATA is a medical technology company developing and marketing...

Medi-Pharm-Logo

AGP starts MediPharm Labs at buy; PT $2 (Canadian)

Alliance Global Partners initiated coverage of MediPharm Labs (TSX:LABS) with a “buy” rating and price target of $2 (Canadian). The stock was quote at 82 cents around midday on Nov. 2. “We see MediPharm in a position to...

Aziyo-Biologics-Logo

Cowen starts Aziyo Biologics at OP; PT $20

Cowen initiated coverage of Aziyo Biologics (NASDAQ:AZYO) with an “outperform” rating an $20 price target. The stock closed at $10.98 on Oct. 30. Aziyo is a regenerative medicine company that has a three-pronged...

T2 Biosystems Logo

AGP ups T2 Biosystems PT to $1.65 from $1.10

Alliance Global Partners raised its price target for T2 Biosystems (NASDAQ:TTOO) to $1.65 from $1.10 after hosting an investor webcast with the company’s CEO and CFO. The stock closed at $1.34 on Oct. 30. “Our...

Strongbridge Biopharma Logo

HCW cuts Strongbridge Biopharma PT to $10 from $18

H.C. Wainwright reduced its price target for Strongbridge Biopharma (NASDAQ:SBBP) to $10 from $18, citing an analysis of the changing dynamics of the Cushing’s syndrome landscape because of competitor programs. The...

DURECT

Chardan starts DURECT at buy; PT $7

Chardan Capital Markets launched coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and price target of $7. The stock closed at $1.76 on Oct. 29. “We expect that DURECT’s lead pipeline asset, DUR-928, will...

Aspira-Women's-Health-Logo

William Blair starts Aspira Women’s Health at OP

William Blair launched coverage of Aspira Women’s Health (NASDAQ:AWH) with an “outperform” rating. The stock closed at $3.63 on Oct. 29. The company’s current product line, the OVA family, is used for presurgical pelvic...